In the April–June 2016 edition of Corporate Disputes, Dr. Gregory K. Bell discusses disputes in the healthcare and life sciences industry. In this roundtable discussion, the panel experts describe the underlying causes of recent disputes in the sector and highlight key cases. To read the article, click the link below.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...